NOTION: iN-home sampling Of cyTokines in ImmunOtherapy patieNts
Research type
Research Study
Full title
A proof of concept study investigating the collection and measurement of in-home dried blood spot samples of cytokines in patients with renal cell carcinoma, metastatic melanoma or non-small cell lung cancer receiving first- line combination immunotherapy.
IRAS ID
272656
Contact name
Louise Carter
Contact email
Sponsor organisation
The Christie NHS Foundation Trust
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Checkpoint inhibitors are immunotherapy drugs that have shown impressive success in treating a range of hard to treat cancers. Treatment related side effects - or immune related adverse events - are often seen with these treatments and are thought to occur in a number of different ways. Treatment will have to be stopped in 20% of patients due to these immune related adverse events, and up to 90% of all patients on checkpoint inhibitors will experience an immune related adverse event.
Cytokines are proteins that are secreted by cells during an inflammatory response. Early evidence suggests that changes in levels of cytokines may differentiate patients who are likely to develop side effects from these treatments from those who do not.
This study will explore the ability of patients on first line combination immunotherapy to sample cytokines at home. The data from this study will be used to evaluate the feasibility of in-home testing and the ability to analyse patients cytokine profiles retrospectively to help feed the development of further studies.
REC name
East of Scotland Research Ethics Service REC 2
REC reference
21/ES/0052
Date of REC Opinion
28 Jun 2021
REC opinion
Further Information Favourable Opinion